Glycosylation by Design with in vitro glycoengineering (IVGE)

In vitro Glycoengineering (IVGE) is a paradigm shift in biotherapeutics glycosylation

A consistent and uniformly glycosylated product is a key criterion in biotherapeutics manufacturing. Currently glycosylation is achieved by optimizing a variety of conditions. This approach may sacrifice yield to achieve the best glycosylation. Glycosylation by Design allows you to uncouple the need to balance between yield and glycosylation. First you can focus on selecting clones that give maximum yield then after producing your protein you can selectively glycosylate it by in vitro glycoengineering (IVGE) resulting in a complete and consistent end product.

Roche CustomBiotech has developed enzymes for Galactosylation and Sialylation along with their substrates. Using these enzymes you can glycosylate your proteins for either galactosylation alone or generate fully sialylated proteins, depending on your therapeutic need.

In vitro glycoengineering (IVGE) that works for you

• Provides complete and consistent glycoform patterns

• Simple "one pot operation"

• Doesn't cause aggregation of the proteins tested *

• Shortens the timeline by at least 30% and increases the production yield by >160% *

• Reduces indirect (e.g. FTEs) and direct costs (e.g. reagents) during scale up *

• Allows selective galactosylation or sialylation of your protein

7 grams of starting material performed in a "single pot reaction"
Mass spectrometry

Reagents for development and production

CustomBiotech portfolio offers all the necessary reagents for IVGE. Roche CustomBiotech has implemented process improvements in manufacturing of these enzymes and sugars keeping in mind that these critical raw materials need to be supplied to you in a cost effective manner, when you employ IVGE strategy for large scale biotherapeutics production.